RecruitingNot ApplicableNCT05982626
Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer
Sponsor
Huashan Hospital
Enrollment
10 participants
Start Date
May 15, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the safety, biodistribution, radiation dosimetry, and uptake in tumor lesions of patients with Her2-positive metastatic breast cancer after injection of \[131I\]/\[68Ga\]SGMIB-ZT-199.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years
Inclusion Criteria7
- Breast cancer patients.
- Women aged between 18 and 75 years old.
- Patients with breast cancer confirmed by histological examination or imaging.
- HER2 positive diagnosis confirmed by puncture by immunohistochemistry or fluorescence in situ hybridization (HER2 positive is defined as immunohistochemistry result of 3+ (IHC 3+); or immunohistochemistry result of 2+/positive in situ hybridization result (IHC 2+/ISH+)).
- Renal function: serum creatinine less than or equal to the upper limit of the normal range; electrocardiogram: no significant abnormalities.
- Patients of childbearing age can cooperate with contraception.
- Willing and able to cooperate with all items of this study.
Exclusion Criteria6
- Subjects meeting any of the following criteria will be excluded from the study:
- Severe hepatic or renal insufficiency;
- Participation in another study protocol or clinical care within the past year that has resulted in radiation exposure exceeding an effective dose of 50 mSv in addition to the radiation exposure expected from participation in this clinical study.
- Participation in this study is considered unsuitable by other investigators.
- Pregnant women and other groups unsuitable to receive radiation.
- Alcohol allergy, etc.
Interventions
RADIATION68Ga/131I-SGMIB-ZT-199
68Ga-SGMIB-ZT-199: PET imaging; 131I-SGMIB-ZT-199: SPECT imaging.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05982626
Related Trials
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT0104237942 locations
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT0710238121 locations
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
NCT074596737 locations
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT048865314 locations
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT053256321 location